These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11204257)

  • 1. Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer.
    Sciarra A; Di Chiro C; Di Silverio F
    World J Urol; 2000 Dec; 18(6):392-400. PubMed ID: 11204257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent androgen deprivation (IAD) in patients with localized prostate cancer and a biochemical progression after radical prostatectomy.
    Sciarra A; Di Chiro C; Voria G; Colella D; Loreto A; Pastore AL; Di Silverio F
    Minerva Urol Nefrol; 2000 Mar; 52(1):1-6. PubMed ID: 11517824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
    Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
    Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
    BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery.
    Sciarra A; Cattarino S; Gentilucci A; Alfarone A; Innocenzi M; Gentile V; Salciccia S
    Urol Oncol; 2013 Jul; 31(5):607-14. PubMed ID: 21665494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Tiguert R; Rigaud J; Lacombe L; Laverdière J; Fradet Y
    J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.
    Grossfeld GD; Chaudhary UB; Reese DM; Carroll PR; Small EJ
    Urology; 2001 Aug; 58(2):240-5. PubMed ID: 11489710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer.
    Aprikian AG; Fair WR; Reuter VE; Sogani P; Herr H; Russo P; Sheinfeld J
    Br J Urol; 1994 Nov; 74(5):630-6. PubMed ID: 7530128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.
    Grossfeld GD; Small EJ; Carroll PR
    Urology; 1998 Jan; 51(1):137-44. PubMed ID: 9457309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study.
    Cookson MS; Sogani PC; Russo P; Sheinfeld J; Herr H; Dalbagni G; Reuter VE; Begg CB; Fair WR
    Br J Urol; 1997 Mar; 79(3):432-8. PubMed ID: 9117227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
    Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
    Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience.
    Peyromaure M; Delongchamps NB; Debré B; Zerbib M
    Urology; 2005 Apr; 65(4):724-9. PubMed ID: 15833516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy.
    Di Silverio F; Sciarra A; Gentile V
    Urology; 2008 May; 71(5):947-51. PubMed ID: 18279940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.
    Calais da Silva F; Calais da Silva FM; Gonçalves F; Santos A; Kliment J; Whelan P; Oliver T; Antoniou N; Pastidis S; Marques Queimadelos A; Robertson C
    Eur Urol; 2014 Aug; 66(2):232-9. PubMed ID: 23582949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.
    Bloom KD; Richie JP; Schultz D; Renshaw A; Saegaert T; D'amico AV
    Urology; 2004 Feb; 63(2):333-6. PubMed ID: 14972484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.